Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial (Q44313160)

1 December 2017

Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial (English)

1 reference

chronic obstructive pulmonary disease

1 December 2017

0 references

author

Jørgen Vestbo

3

1 reference

1 December 2017

Peter Calverley

1

1 reference

1 December 2017

Romain Pauwels

2

1 reference

1 December 2017

Paul Jones

4

1 reference

1 December 2017

Neil Pride

5

1 reference

1 December 2017

Amund Gulsvik

6

1 reference

1 December 2017

Julie Anderson

7

1 reference

1 December 2017

Claire Maden

8

1 reference

1 December 2017

TRial of Inhaled STeroids ANd long-acting beta2 agonists study group

9

1 reference

1 December 2017

language of work or name

English

0 references

publication date

1 February 2003

1 reference

1 December 2017

1 reference

1 December 2017

361

1 reference

1 December 2017

9356

1 reference

1 December 2017

449-456

1 reference

A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire

1 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912459-2

7 January 2021

Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912459-2

7 January 2021

Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912459-2

7 January 2021

Use of a long-acting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912459-2

7 January 2021

Efficacy of salmeterol xinafoate in the treatment of COPD

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912459-2

7 January 2021

Efficacy, tolerability, and effects on quality of life of inhaled salmeterol and oral theophylline in patients with mild-to-moderate chronic obstructive pulmonary disease. SLMT02 Italian Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912459-2

7 January 2021

Quality of life changes in COPD patients treated with salmeterol

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912459-2

7 January 2021

Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912459-2

7 January 2021

Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912459-2

7 January 2021

Alternative mechanisms for long-acting beta(2)-adrenergic agonists in COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912459-2

7 January 2021

Inhaled corticosteroids are not beneficial in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912459-2

7 January 2021

Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912459-2

7 January 2021

Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912459-2

7 January 2021

Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912459-2

7 January 2021

Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912459-2

7 January 2021

Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912459-2

7 January 2021

Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912459-2

7 January 2021

Aerosolized beclomethasone in chronic bronchitis. Improved pulmonary function and diminished airway inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912459-2

7 January 2021

Reliability and validity of the chronic respiratory questionnaire (CRQ).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912459-2

7 January 2021

An empirical comparison of the St George's Respiratory Questionnaire (SGRQ) and the Chronic Respiratory Disease Questionnaire (CRQ) in a clinical trial setting

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912459-2

7 January 2021

Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912459-2

7 January 2021

Quality of life and hospital re-admission in patients with chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912459-2

7 January 2021

Do long-acting beta2-adrenoceptor agonists enhance the anti-inflammatory effect of glucocorticoids in asthma?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912459-2

7 January 2021

Exercise capacity predicts health status in alpha(1)-antitrypsin deficiency

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912459-2

7 January 2021

Scientific rationale for inhaled combination therapy with long-acting beta2-agonists and corticosteroids

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912459-2

7 January 2021

10.1016/S0140-6736(03)12459-2

Identifiers

DOI

1 reference

1 December 2017

1 reference